$Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma$

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Background: The use of a clonal master engineered induced pluripotent stem cell (iPSC) line as a renewable source for the mass production of immune effector cells offers distinct advantages over existing patient (pt)- and donor-derived cell-based cancer immunotherapy approaches, including off-the-sh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.823-823
Hauptverfasser:	Bachanova, Veronika, Ghobadi, Armin, Patel, Krish, Park, Jae H, Flinn, Ian W., Shah, Prutha, Wong, Carol, Bickers, Cara, Szabo, Peter, Wong, Lilly, Valamehr, Bahram, Atwal, Siminder, Chu, Yu-Waye, Elstrom, Rebecca, Strati, Paolo
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!